Pemazyre for Myeloid/lymphoid neoplasms with FGFR1 rearrangement
Quick answer: Pemazyre is used for Myeloid/lymphoid neoplasms with FGFR1 rearrangement as part of a fgfr tyrosine kinase inhibitor treatment regimen. Pemigatinib selectively inhibits fibroblast growth factor receptors 1-3 to block oncogenic FGFR signaling in tumor cells The specific dosing for Myeloid/lymphoid neoplasms with FGFR1 rearrangement is determined by your prescriber based on individual factors.
Why is Pemazyre used for Myeloid/lymphoid neoplasms with FGFR1 rearrangement?
Pemazyre belongs to the FGFR tyrosine kinase inhibitor class. Pemigatinib selectively inhibits fibroblast growth factor receptors 1-3 to block oncogenic FGFR signaling in tumor cells This action makes it useful for treating or managing Myeloid/lymphoid neoplasms with FGFR1 rearrangement in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Pemazyre is the right choice for a specific patient depends on the type and severity of Myeloid/lymphoid neoplasms with FGFR1 rearrangement, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Myeloid/lymphoid neoplasms with FGFR1 rearrangement
Common adult dosing range: 13.5 mg orally once daily, 14 days on / 7 days off. The actual dose for Myeloid/lymphoid neoplasms with FGFR1 rearrangement depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Pemazyre medicine page.
What to expect
Pemazyre treatment for Myeloid/lymphoid neoplasms with FGFR1 rearrangement typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Myeloid/lymphoid neoplasms with FGFR1 rearrangement
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Pemazyre is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all FGFR tyrosine kinase inhibitor for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Pemazyre
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Pemazyre full prescribing information · All FGFR tyrosine kinase inhibitor alternatives
Frequently asked questions
How effective is Pemazyre for Myeloid/lymphoid neoplasms with FGFR1 rearrangement?
Effectiveness varies by individual response, dose, and severity. Pemazyre is one of several treatment options for Myeloid/lymphoid neoplasms with FGFR1 rearrangement, supported by clinical evidence within the fgfr tyrosine kinase inhibitor class. Discuss expected response with your prescriber.
How long do I need to take Pemazyre for Myeloid/lymphoid neoplasms with FGFR1 rearrangement?
Treatment duration depends on the nature of Myeloid/lymphoid neoplasms with FGFR1 rearrangement — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Pemazyre when used for Myeloid/lymphoid neoplasms with FGFR1 rearrangement?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Pemazyre for Myeloid/lymphoid neoplasms with FGFR1 rearrangement?
Yes. Multiple medicines and non-drug options exist for Myeloid/lymphoid neoplasms with FGFR1 rearrangement. Alternatives within the fgfr tyrosine kinase inhibitor class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.